Purpose: Occasionally, pancreaticobiliary cancer presents as a relatively indolent disease and localized blood-borne lung metastases may be resectable. We reviewed our experience with therapeutic lung resections in pancreatic cancer patients.
Methods: In a retrospective cohort study of pancreatic cancer patients who underwent subsequent therapeutic lung resections, from 1996 to 2015, all clinical data were gathered for comparison between patients undergoing pancreatic pulmonary metastasectomy and those undergoing lung resection for other diseases.
Results: Among 29 patients with definitively treated pancreaticobiliary cancer who underwent lung resections with curative intent, 16 patients (55%) had resection of isolated pancreaticobiliary cancer metastases (group A) and 13 patients (45%) had 15 resections of primary lung cancers, and one granuloma (group B). No surgical complications or operative mortalities occurred. The median disease-free interval (DFI) from definitive pancreatic cancer treatment to pulmonary metastasectomy or other nonmetastasectomy therapeutic lung resection was 24.0 and 8.0 months, respectively. The estimated median overall survival after lung resection was 33 months for all patients (95% confidence interval: 0, 67) and 28 months for the group A pulmonary metastasectomy patients (95% confidence interval: 16, 40), corresponding to an estimated 5-year survival rate of 47% and 37%, respectively. Serum CA 19-9 level before lung resection significantly predicted mortality: adjusted hazard ratio 1.38 (95% confidence interval: 1.09, 1.74) per each 100-unit increment, P ¼ .006.
Conclusions:
Although pancreaticobiliary cancers have an overall dismal prognosis, we recommend pulmonary metastasectomy in highly selected patients. Additionally, not all new lung masses in pancreatic cancer patients are metastases, and resection should be considered, for a second primary lung cancer is often found. (J Thorac Cardiovasc Surg 2016;152:75-82) K-M survival of metastasectomy and primary lung cancer resection in pancreatic cancer.
Central Message
Pulmonary metastasectomy may be appropriate in selected pancreatic cancer patients, but not all lung masses in these patients are metastases, and a second primary lung cancer may warrant resection.
Perspective
Although pancreaticobiliary cancers generally have a dismal prognosis, some patients may subsequently develop isolated, metastatic disease in the lungs. In highly selected patients, pulmonary metastasectomy offers a safe, therapeutic option. Not all new lung masses in pancreatic cancer patients are metastases, so resection should be considered, as a second primary lung cancer is often found.
See Editorial Commentary page 83.
Pancreatic and biliary carcinomas continue to be highly lethal diseases, with an estimated 48,960 new cases and 40,560 deaths in 2015, according to American Cancer Society data, with a median survival of 12.6 months, and a 5-year survival of 7%. 1 Of the 20% of patients who have localized disease and are undergoing resection of the cancer, the 3-year, disease-specific survival is still only 27%. 2 Among long-term survivors, a common place for recurrence is the lung, and occasionally the recurrence is solitary. 3 Pulmonary metastasectomy is a well-recognized therapeutic procedure for selected patients who have many stage IV solid tumors, with numerous published retrospective series reporting long-term survivors from sarcoma, colorectal cancer, renal cell carcinoma, melanoma, and other cancers. 4 In the International Registry of Lung Metastases, the reported overall 5-year survival rate for all histologies combined is 36%. 5 Nevertheless, these reports are from retrospective series, because no prospective randomized trials have been conducted. Offering pulmonary metastasectomy as a therapeutic procedure is based on the observation that long-term survival in stage IV cancers is seen only after resection, and not with even the best systemic therapy alone. In fact, the apparent survival benefit of controlling isolated lung lesions in higher-risk surgical patients has led to exploring use of percutaneous, image-guided ablation. 6 However, to our knowledge, only a few reports of pulmonary metastasectomy for pancreaticobiliary carcinoma are available in the literature, 3, 7 although in a highly select subset of patients, this option is reasonable. Therefore, we chose to review our institutional experience in pulmonary metastasectomy for pancreaticobiliary carcinoma, looking at not only confirmed cases of metastases, but also cases with suspected metastases that turned out to have a different disease process.
METHODS

Patient Data
We conducted a retrospective cohort study of all primary pancreatic and biliary carcinoma patients who, after definitive treatment (pancreaticoduodenectomy or concurrent chemoradiotherapy) of their primary malignancy, underwent a pulmonary resection at Moffitt Cancer Center, between July 1, 1996 and October 1, 2015. Approvals for this retrospective chart review study were obtained from the Moffitt Scientific Review Committee and the University of South Florida Institutional Review Board.
The Moffitt Tumor Registry database was queried for consecutive pancreatic and biliary cancer patients who underwent a lung resection as well. From this group, eligible patients were those who had no active site of disease outside of the lungs, and in whom the pulmonary resection was intended to remove all of the disease present in the lungs, thus meeting the standard criteria for pulmonary metastasectomy. 4 The preoperative clinical assumption was that a new lung lesion in a pancreatic cancer patient was a metastasis. Usually a metastasis has the radiographic appearance of lung mass that is typically round, with sharp, discrete borders. For other patients, the radiographic appearance of a spiculated, irregular mass was more likely to be primary lung cancer. Often, but not always, the pathology was correlated with the preoperative radiographic suspicion. Electronic medical records were reviewed for pertinent clinical information.
The decision to proceed with lung surgery was made after full restaging by chest and abdominal computed tomography (CT) and positron emission tomography (PET) scans (beginning in 2000) that indicated no extrapulmonary disease, and after patients were presented at both the gastrointestinal and thoracic multidisciplinary oncology conferences. All surgical procedures were performed by board-certified thoracic surgeons and were planned as a pulmonary metastasectomy with curative intent. If the lung lesion was resectable as an oligometastasis or primary lung cancer, we did not do a fine-needle aspirate first, but proceeded to resection because the result would not change management, and this procedure has a definite morbidity and cost.
Additionally, if a fine-needle aspirate is performed and shows cancer, distinguishing a primary lung cancer from a metastasis is very difficult, unless it is not an adenocarcinoma. The only time we performed a fine-needle aspirate was when we found numerous nodules (too many for a realistic metastasectomy) and the fine-needle aspirate was used just to verify the diagnosis before the patient received additional chemotherapy. At the time of surgery, a frozen section was obtained on the resected lung mass to aid, when possible, in determining whether a moreextensive resection was indicated. A minimally invasive surgical approach was used whenever feasible. The decision for adjuvant therapy after lung resection was made for selected cases.
Clinical Results
Outcomes, including postoperative complications and length of stay, were extracted. Disease-free interval (DFI) was defined as the time from primary pancreaticobiliary tumor resection or definitive chemoradiotherapy completion to the date of the lung resection. Vital statistics were obtained from the Moffitt Cancer Registry, hospital records with clinic notes, outside physician records, and the Social Security Death Index.
Histologic Evaluation
Gastroenterology pathologists, in consultation with thoracic pathologists, reviewed all pathology specimens from the pancreaticobiliary cancers and the subsequent lung resections. The pathologic determination of whether a resected lung tumor was a pancreaticobiliary metastasis or a primary lung cancer was made based on: (1) direct histologic comparison of the tumors; and (2) immunohistochemistry staining characteristics of the tumors, especially CK7, TTF-1, and napsin-A positive for primary lung adenocarcinomas; and CK-7, CK-17/18, and CA 19-9 positive, or loss of DPC4, for pancreatic cancers. Rarely, the clinical data and radiographs, as well as an outside pathologic consultation, were used to substantiate the diagnosis of metastatic disease when the pathology was not definitive.
Some patients underwent lung resection for suspected metastatic disease that was histologically documented as pancreaticobiliary carcinoma by the evaluation described (group A). Some patients who underwent lung surgery with a history of a fully treated pancreaticobiliary malignancy were found to have instead a second primary lung cancer or benign disease (group B).
Statistical Analysis
Descriptive statistics, including frequency and percentage for categoric variables, as well as median and range for continuous variables, were obtained. Either Pearson Chi-square or Fisher's exact test was used to compare categoric variables, whereas a 1-way analysis of variance was used to compare continuous variables. Overall survival was calculated from the date of first therapeutic lung resection to the date of last follow-up, or death. Survival estimates were obtained using the Kaplan-Meier method. A multivariable Cox proportional hazards model was fitted to estimate the strength of association between survival and clinical variables of interest. Variables with missing values were excluded from analyses. Analyses and graphic presentations were performed using SPSS, version 22 (Chicago, Ill).
RESULTS
Demographics
During the study period, a total of 29 patients were identified; 16 underwent resection of pancreaticobiliary
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metastases (group A), and 13 underwent 15 lung resections of what ultimately proved to be primary lung cancer in 12 patients and fungal disease (Cryptococcus) in 1 patient (group B). In all but 2 cases (93.1%), the lung resections were done in the past 10 years, indicating an increasing trend in pulmonary metastasectomy in pancreatic cancer patients. To give this series some context, during the past 10 years, 1129 pancreatic resections were done at our institution.
The median age of patients at the time of pancreatic cancer treatment was 61.5 (range: 36-81 years) in group A, and 71.0 (range: 54-79) years in group B; P ¼ .01. Ten patients (34%) were male. Nineteen patients were current or former smokers, who had a median smoking history of 37.2 (range: 15-75) pack-years; 15 of 29 (52%) patients never drank ethanol; and only 2 (7%) patients had a moderately heavy daily ethanol intake.
Demographic, disease-, and treatment-related data for the 2 groups are shown in Tables 1 and 2 . The typical computed tomography scan appearance of a pancreatic pulmonary metastasis in a group A patient (No. 5) is shown in Figure 1 , A, and a typical lung cancer in a group B patient (No. 4) is shown in Figure 1 , B.
Pancreaticobiliary Cancer Treatment
One patient in each group had a small, but locally invasive, unresectable tumor and was treated nonsurgically with definitive chemotherapy and stereotactic body radiotherapy. The other 27 patients underwent surgery. Four of 29 (13.8%) patients had cholangiocarcinomas; the remainder had pancreatic adenocarcinomas. Of the patients who were surgically treated, 13 of 15 in group A, and 6 of 12 in group B underwent adjuvant therapy. Before treatment, the median preoperative CA 19-9 (normal value 35) in group A was 285 (range: 3-1550); in group B, the median preoperative CA 19-9 level was 189 (range: 2-14,036). No statistical difference was found between groups. In 8 patients, the preoperative CA 19-9 level was unknown.
Lung Resections
In Group A patients, pulmonary metastasectomy was performed after a median DFI of 24.0 (range: 0-68 months). The median length of hospital stay was 3 (range: 1-9) days. The only complications occurred in 3 patients who had prolonged air leaks over 5 days (all had significant emphysema); no operative mortality occurred.
In group B patients, lung resections were performed with a median DFI of 8.0 (range: 0-108 months) after their pancreatic cancer resection. No significant difference in the DFI between group A and B was observed (P ¼ .78). However, in 3 patients, the lung lesion was found synchronously with the pancreatic cancer, and based on the radiographic appearance, was thought likely to be a second primary lung cancer. The lung cancer in each patient was resected as soon as the patient completely recovered from the pancreatic surgery. The median length of stay in group B was 4.5 (range: 2-12 days). The only complications were seen in 3 patients who had prolonged air leaks over 5 days (all had significant emphysema as well), and no operative mortality occurred. No significant difference in the serum CA 19-9 before lung surgery between group A and B was observed: mean 138 versus 113.
Pathology
In with an unknown stage. Ten patients had pancreatic adenocarcinomas, and 3 had cholangiocarcinomas. When the pulmonary findings were discounted, no differences were found in the stage of pancreaticobiliary cancer between groups; P ¼ .53.
Survival and Predictors of Survival
At the time of analysis, 12 of 29 patients had died ( Figure 2) . The median overall survival of the entire cohort was 33 months (95% confidence interval [CI]: 0, 67). This corresponded to an estimated 5-year survival rate of 47%.
In group A, 7 of 16 patients had died ( Figure 3 ). The median overall survival was 28 months (95% CI: 16, 40), corresponding to an estimated 5-year survival rate of 37.1%. In group B, 5 of 13 patients had died (Figure 3) . The median overall survival was 78 months (95% CI: 0, 161), corresponding to an estimated 5-year survival rate of 60.1%.
Based on major patient variables (age, gender, patient group, DFI, stage of pancreatic cancer, CA 19-9 levels before pancreatic resection, and before lung resection), in this small patient population, the univariable analysis model indicated that the serum CA 19-9 level before lung resection significantly predicted overall survival, with a hazard ratio (HR) of 1.38 (95% CI: 1.09, 1.74) per 100 units of CA 19-9 increment; P ¼ .006. In the multivariable analysis model, the only significant variable is the CA 19-9 level prior to lung resection. No difference was found in mortality: HR 1.85 (95% CI: 0.48, 7.41); P ¼ .37. The stage of the pancreaticobiliary cancer, group, DFI, age, gender, or CA 19-9 level before pancreatic resection, were not predictive of survival.
DISCUSSION
Pulmonary metastasectomy as therapy for selected patients with lung metastases in stage IV solid tumors, such as colorectal carcinoma, sarcomas, renal cell carcinoma, melanoma, and others, has been a wellrecognized surgical option for decades. 4 Based on numerous retrospective case series, metachronous and even synchronous metastases may be resected with an expected mean 5-year survival of 36% for all histologies combined. 5 However, pancreaticobiliary carcinoma generally has not been included in the tumor types considered for metastasectomy. In fact, the dismal 5-year overall survival of 7% for this malignancy (1% in stage IV patients) has generated widespread pessimism, if not therapeutic nihilism, by the medical community. 1 In general, most oncologists think that any pancreatic cancer patient who has or develops a lung mass is most likely to have stage IV pancreatic cancer, and only palliative chemotherapy is recommended. Even if the lung lesion is known to be a lung cancer, surgery is generally not recommended, based on the reasoning that the pancreatic cancer will kill the patient long before the stage I lung cancer will harm the patient. Fortunately, this reasoning seems to be flawed, and here, we report our experience with metastasectomy for pancreaticobiliary cancers that have an estimated 5-year survival of 37%.
This survival number is impressive, given the fact that by the time a diagnosis is made, pancreatic and biliary carcinomas generally tend to be locally advanced or metastatic, for lack of any effective screening techniques. Still, at least 20% of patients have early-stage, potentially resectable tumors, although an estimated 40% of candidates do not undergo resection. 3 Even with resection, local recurrence, or distant spread, usually to the lung, are the limiting factors for cure. Nevertheless, advancements in systemic therapy and less-toxic, more-effective radiotherapy have improved patients' outlook. Therefore, entertaining pulmonary metastasectomy in pancreaticobiliary carcinoma is a logical consideration as long as the standard criteria are met for this potentially curative surgical procedure.
Six general criteria, as documented by numerous clinical series, realistically qualify a patient for pulmonary metastasectomy, with the expectation of potential therapeutic benefit: (1) the primary cancer is resected or completely controlled (with definitive chemoradiotherapy); (2) a limited number of metastases occur in the lungs (usually 5); (3) all lung metastases can be removed; (4) the patient can tolerate the necessary lung resection(s); (5) no evidence indicates that metastases occur outside of the lungs; and (6) no better alternative treatments are available (a rare option). 4 By objectively applying these criteria to our pancreaticobiliary carcinoma patient population, 29 patients during the past 20 years at our tertiary-care institution qualified for lung resection with therapeutic intent. Notably, 93.1% of We did not find DFI to be helpful in differentiating pulmonary metastasis from primary lung cancer. Of the 29 patients undergoing lung resection with curative intent for presumed metastatic disease from pancreatic or biliary cancer, the resected lung lesions in 16 (55.5%) were histologically proven to be metastases (group A), with a median DFI of 24 months. In most series of various tumor types, a long DFI over the course of 2 years offers a survival advantage. 4 Nevertheless, several patients in our series with a much shorter DFI (<12 months) had prolonged postmetastasectomy survival. In the other 13 patients, with a total of 15 lung resections (group B) after a median DFI of 8.0 months, all resected lesions were T1N0 or T2N0, primary non-small cell lung cancers (5 squamous cell carcinomas and 9 adenocarcinomas), except in 1 patient who had resection of 2 active Cryptococcus granulomata.
All lung resections were safely performed with a short median length of hospital stay of 3 days in group A, and 4.5 days in group B. The only complications were a prolonged air leak over 5 days in 3 patients in each group (all current or former heavy smokers with significant emphysema), and no surgical mortality occurred.
During the study period, 12 of 29 (41%) patients died, although only 50% of the deaths were related to pancreatic cancer recurrence. The median survival after lung resection in the pulmonary metastasectomy group A was 28 months. To our knowledge, the best reported median survival of pancreatic carcinoma patients with metastatic stage IV disease who are treated with optimal chemotherapy is only 11.1 months. 8 In addition, the estimated 5-year survival rate is 37%, which compares favorably to the mean 5-year survival of 36% for all histologies combined, as reported by the International Registry of Lung Metastases. 5 Even more impressive is the group A overall postpancreatectomy median survival of 52 months, with 3 of these patients alive with known disease at 79, 57, and 45 months. Obviously, these patients have a far more indolent cancer than the usual pancreaticobiliary malignancy.
In the nonmetastatectomy resection group B, the median overall survival was 78 months, likely indicating the fact that most members of this group were cured of their pancreaticobiliary cancer by their primary therapy. Only 1 patient in group B died with known recurrent pancreatic cancer.
Prior Series
The earliest reports of pulmonary metastasectomy for pancreatic carcinoma were summarized by Kitasato and colleagues. 7 Their 2012 paper presents a single case report and then collects a total of 20 cases in 12 published series from Japan, beginning in 2002. In these cases, the DFI was long at 43 (range: 11-163) months, even longer than the DFI in the current series. A total of 94% of their cases with a known stage were at least stage II or greater, and all had adjuvant chemotherapy after pancreatectomy. After a median follow-up of 19.5 (range: 2-66) months, 75% of their patients were alive. The lung surgery was reported as being safe, with minimal morbidity and no mortality.
Arnaoutakis and colleagues 3 in 2011 published their series of 9 patients undergoing pulmonary metastasectomy for pancreatic carcinoma, comparing them with 21 other patients who had pancreatic metastases isolated to the lungs and did not undergo pulmonary resection, apparently because they were less healthy overall. In addition, nearly one third of their non-pulmonary metastasectomy group had only an R1 pancreatic resection, compared with a complete R0 resection in their metastasectomy group. The lung surgical procedures in the 9 metastasectomy patients were performed safely, with no mortality and a mean hospital stay of 4.2 AE 3.4 days. As expected, the metastasectomy patients had a longer 18.6 months as a median survival after resection than the median 7.5 months of survival in the nonsurgical group. Unlike the Arnaoutakis and colleagues' series, all patients in the current series who met the criteria for potential curative pulmonary metastasectomy underwent lung resection.
Limitations
The current study suffers from the inherent limitations to any retrospective series that has a small sample size and potential for selection and lead-time bias. Although this is the largest single-institution series published, the numbers are still small, likely owing to the relative rarity of patients who meet the criteria for pulmonary metastasectomy in pancreaticobiliary carcinoma. Likewise, the role of pulmonary metastasectomy in pancreaticobiliary cancer is unlikely to be studied in a prospective randomized trial, owing to the limited number of patients who qualify for this approach, and the long-term outcomes of such patients who do not undergo pulmonary metastasectomy remain unknown.
As in the pulmonary metastasectomy literature for other solid tumors, such as colorectal cancer, some believe that much of the apparent benefit may result purely from the selection of patients who are in good health with good biology and with relatively indolent disease, who most likely survive based on specific prognostic factors. Perhaps having a metastasectomy, for most patients, does not alter materially their long-term survival? To answer this question, a randomized trial is accruing, albeit very slowly, in Britain and Europe (The Pulmonary Metastasectomy in Colorectal Cancer [PulMiCC] trial), in which candidates who meet the criteria for pulmonary metastasectomy are randomized to surgery, versus medical therapy, with long-term survival as the primary endpoint. 9 Therefore, bearing in mind the limitations in study design, our data can be used cautiously to guide therapy. Future improvements in systemic therapy of pancreaticobiliary carcinoma may result in more patients living long enough to have isolated resectable metastases.
CONCLUSIONS
A subset of pancreaticobiliary cancer patients may have relatively indolent disease, with long disease-free intervals that may derive enhanced long-term survival from pulmonary metastasectomy. The operative procedure, either using thoracotomy or a minimally invasive approach in this patient population, is very low-risk surgery that may be done safely with minimal morbidity and no mortality. Pancreaticobiliary cancer should be added to the list of solid tumors that may derive therapeutic benefit from pulmonary metastasectomy when they meet the standard criteria, especially if they have a low preoperative serum CA 19-9 level. Additionally, not all new lung masses in pancreatic cancer patients are metastases, and resection should be
